Sunepitron (developmental code name CP-93,393) is a combined 5-HT1A receptor agonist and α2-adrenergic receptor antagonist. It was previously under development by Pfizer for the treatment of depression and anxiety. It made it to phase III clinical trials before being discontinued.
{{Drugbox | IUPAC_name = 1-{[2-(pyrimidin-2-yl)octahydro-2H-pyrido[1,2-a]pyrazin-7-yl]methyl}pyrrolidine-2,5-dione | image = Sunepitron.png | image_class = skin-invert-image | width =
| tradename = | pregnancy_category = | legal_status = | routes_of_administration = Oral
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).